Zobrazeno 1 - 6
of 6
pro vyhledávání: '"E. H. Paschold"'
Autor:
Frances A. Shepherd, Philip Clingan, Mark A. Socinski, Markus F. Renschler, Martin Steins, Jose Manuel Trigo, J. Mezger, Jeffrey A. Bubis, R. McNally, E. H. Paschold, Lionel Bosquée, Martin Reck, J. von Pawel, Spigel, Wolfgang Schuette, Kristiaan Nackaerts, Robert M. Jotte, Paul Lorigan, M. O'Brien, Manuel Domine
Publikováno v:
ResearcherID
Aims: Amrubicin, a 3rd gen. anthracycline and potent topoisomerase II inhibitor, has shown activity in SCLC. ACT-1 compared the safety and efficacy of amr vs. topo for 2nd line treatment of SCLC. Methods: 637 pts were random. 2:1 amr 40mg/m2 IV d 1
Publikováno v:
The American surgeon. 67(6)
Hypercalcemia is a well-known manifestation of paraneoplastic syndromes associated with a variety of malignancies. However, colon cancer has only rarely been associated with hypercalcemia of malignancy. We present the case of a patient with recurrent
Autor:
Marianna Koczywas, Mark A. Socinski, Geoffrey I. Shapiro, R. K. Blackman, Kwok-Kin Wong, E. H. Paschold, Jonathan W. Goldman, Leora Horn, J. M. Lufkin, Florentina Teofilovici
Publikováno v:
Journal of Clinical Oncology. 29:7500-7500
7500 Background: Ganetespib is a potent, next-generation Hsp90 inhibitor that is structurally unrelated to the first-generation ansamycin class of Hsp90 inhibitors and has shown superior activity to these agents in preclinical studies. Ganetespib has
Autor:
H B, Muss, E H, Paschold, W R, Black, M R, Cooper, R L, Capizzi, R, Christian, J M, Cruz, D V, Jackson, J J, Stuart, F, Richards
Publikováno v:
Seminars in oncology. 12(1 Suppl 1)
One hundred twenty-four patients with recurrent or metastatic breast cancer were randomized to receive megestrol acetate 40 mg orally, four times daily, or tamoxifen 10 mg orally twice daily. If therapy failed patients were crossed over to the altern
Autor:
D V, Jackson, E H, Paschold, C L, Spurr, H B, Muss, F, Richards, M R, Cooper, D R, White, J J, Stuart, J O, Hopkins, R, Rich
Publikováno v:
Cancer. 53(12)
Twenty-five patients with a variety of histologic types of advanced non-Hodgkin's lymphoma refractory to previous chemotherapy were entered into a trial of vincristine infusion. Patients received 5-day courses of vincristine 0.25 mg/m2/day by continu
Autor:
E H, Paschold, H B, Muss
Publikováno v:
American family physician. 24(3)
Current trials are aimed at determining whether less radical surgery or irradiation is equivalent to radical or modified radical mastectomy. Axillary node involvement is the most reliable indicator of prognosis. Patients with axillary node involvemen